These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8337847)

  • 21. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.
    Roof P; Ricci M; Genin P; Montano MA; Essex M; Wainberg MA; Gatignol A; Hiscott J
    Virology; 2002 Apr; 296(1):77-83. PubMed ID: 12036319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions between Tat of HIV-2 and transcription factor Sp1.
    Pagtakhan AS; Tong-Starksen SE
    Virology; 1997 Nov; 238(2):221-30. PubMed ID: 9400595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the small leader exons 2 and 3 on human immunodeficiency virus type 1 gene expression.
    Krummheuer J; Lenz C; Kammler S; Scheid A; Schaal H
    Virology; 2001 Aug; 286(2):276-89. PubMed ID: 11485396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cooperativity between Rad51 and C/EBP family transcription factors modulates basal and Tat-induced activation of the HIV-1 LTR in astrocytes.
    Chipitsyna G; Sawaya BE; Khalili K; Amini S
    J Cell Physiol; 2006 Jun; 207(3):605-13. PubMed ID: 16511829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
    Jiang MC; Lin JK; Chen SS
    Biochem Biophys Res Commun; 1996 Sep; 226(1):1-7. PubMed ID: 8806583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular approaches to inhibit HIV-1 tat expression and functions.
    Grossi MP; Caputo A; Zucchini S; Bozzini R; Marconi PC; Manservigi R; Barbanti-Brodano G; Balboni PG
    Year Immunol; 1993; 7():199-204. PubMed ID: 8396820
    [No Abstract]   [Full Text] [Related]  

  • 27. Structure and expression of the equine infectious anemia virus transcriptional trans-activator (tat).
    Derse D; Dorn P; DaSilva L; Martarano L
    Dev Biol Stand; 1990; 72():39-48. PubMed ID: 2178129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tat-induced lesions in transgenic mice do not correlate with the HIV-1 LTR transactivation.
    Fergelot P; Molina T; Blanchet P; Grimber G; Duquenne O; Couton D; Zider A; Briand P; Cavard C
    C R Acad Sci III; 1995 Mar; 318(3):329-37. PubMed ID: 7788501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional analysis of the N-terminal domain of Tat protein of the human immunodeficiency virus type 1.
    Reddy MV; Desai M; Jeyapaul J; Prasad DD; Seshamma T; Palmeri D; Khan SA
    Oncogene; 1992 Sep; 7(9):1743-8. PubMed ID: 1501886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient trans-activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure.
    Berkhout B; Gatignol A; Silver J; Jeang KT
    Nucleic Acids Res; 1990 Apr; 18(7):1839-46. PubMed ID: 2186367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Codelivery to mammalian cells of a transcriptional factor with cis-acting element using cationic liposomes.
    Farhood H; Gao X; Barsoum J; Huang L
    Anal Biochem; 1995 Feb; 225(1):89-93. PubMed ID: 7778790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelin/granulin growth factors: extracellular cofactors for HIV-1 and HIV-2 Tat proteins.
    Trinh DP; Brown KM; Jeang KT
    Biochem Biophys Res Commun; 1999 Mar; 256(2):299-306. PubMed ID: 10079180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors.
    Gatignol A; Duarte M; Daviet L; Chang YN; Jeang KT
    Gene Expr; 1996; 5(4-5):217-28. PubMed ID: 8723388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional comparison of the basic domains of the Tat proteins of human immunodeficiency virus types 1 and 2 in trans activation.
    Elangovan B; Subramanian T; Chinnadurai G
    J Virol; 1992 Apr; 66(4):2031-6. PubMed ID: 1548750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA.
    Rhim H; Rice AP
    Nucleic Acids Res; 1994 Oct; 22(21):4405-13. PubMed ID: 7971271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The full-length Tat protein is required for TAR-independent, posttranscriptional trans activation of human immunodeficiency virus type 1 env gene expression.
    Kim YS; Panganiban AT
    J Virol; 1993 Jul; 67(7):3739-47. PubMed ID: 8510203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells.
    Alonso A; Derse D; Peterlin BM
    J Virol; 1992 Jul; 66(7):4617-21. PubMed ID: 1602563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.
    Kolson DL; Collman R; Hrin R; Balliet JW; Laughlin M; McGann KA; Debouck C; Gonzalez-Scarano F
    J Gen Virol; 1994 Aug; 75 ( Pt 8)():1927-34. PubMed ID: 8046394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation.
    Verhoef K; Bauer M; Meyerhans A; Berkhout B
    AIDS Res Hum Retroviruses; 1998 Nov; 14(17):1553-9. PubMed ID: 9840288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The number of positively charged amino acids in the basic domain of Tat is critical for trans-activation and complex formation with TAR RNA.
    Delling U; Roy S; Sumner-Smith M; Barnett R; Reid L; Rosen CA; Sonenberg N
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6234-8. PubMed ID: 2068104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.